Cephalon's Baldino, CEO and founder, dies at 57

Cephalon ($CEPH) Chairman and CEO Frank Baldino, Jr. (photo) died last night, leaving the company without a permanent chief. It was recently announced that Baldino, 57, who had been on medical leave since August, would be on leave "indefinitely." COO Kevin Buchi has been running the company in his absence. Calling Baldino a "pioneer" in the industry, the company said in a statement, "[H]e was an inspirational leader who will be sorely missed."

Baldino founded Cephalon 20 years ago and took the company from start-up to publicly traded drugmaker with eight products in the U.S. and more than $2 billion in revenues. It is best known for its sleep-disorder remedies Provigil and Nuvigil, but it also makes therapies for cancer and other central nervous system disorders. Provigil has won fame not only as a blockbuster seller, but as an off-label performance booster used by some students--and even research scientists--to sharpen their thinking.

To counter the loss of Provigil sales when it faces generic competition, the company recently bought a stake in Mesoblast, an Australian company working on stem-cell therapies in a record-setting deal that could be worth more than $2 billion. Buchi wrapped up that deal, and he's set to join Mesoblast's board of directors.

So will Buchi end up in the CEO seat? The company's spokesman tells Reuters that it's not going to make any succession announcements "in the near future," out of respect for Baldino's leadership. Absent that leadership, it is unknown whether Cephalon will continue its upward path.

- get the release from Cephalon
- see the Reuters news
- get Baldino's company bio

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.